(NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, is working together with ...

Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual ...

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. OCX has been the topic of a ...

EDT OncoCyte (OCX) files to sell 10.61M shares of common stock for holdersDon't Miss Our End of Quarter Offers: Discover the latest ...

Fintel reports that on March 28, 2025, Lake Street initiated coverage of OncoCyte (NasdaqCM:OCX) with a Buy recommendation.

Lake Street 分析师认为，OncoCyte 目前的市场估值并未反映公司的潜力，表明当前股价为长期投资者提供了一个有吸引力的入场点。该公司启动覆盖并给予"买入"评级和5美元的目标价是基于这些因素，表明对 OncoCyte 未来表现的信心。随着公司下一次财报将于4月4日发布，投资者可以通过 InvestingPro ...

Lake Street initiated coverage of OncoCyte (OCX) with a Buy rating and $5 price target Oncocyte has “an ambitious plan to upend the current ...

OncoCyte (NASDAQ:OCX – Get Free Report)‘s stock had its “equal weight” rating reiterated by research analysts at Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $4.00 ...

Q4 2024 Earnings Call Transcript March 24, 2025 OncoCyte Corporation misses on earnings expectations. Reported EPS is ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Discover OncoCyte's Q4 2024 progress with its cutting-edge kidney transplant test. Insights on FDA ambitions, market strategies & financial runway.

Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, ...